Safety of different combinations of tenofovir tablets in the treatment of AIDS
替诺福韦片不同组合治疗艾滋病的安全性

摘要

目的 探究分析替诺福韦片不同组合治疗艾滋病的安全性。方法 选取2018年2月-2022年2月在我院接受治疗的98例艾滋病患者作为研究对象，随机分为对照组与研究组。对照组使用依非伟伦+替诺福韦+拉米夫定治疗，研究组使用拉米夫定+替诺福韦+克立芝治疗，治疗后对比两组淋巴细胞计数、HIV病毒载量、临床指标及肾毒性、骨密度影响的发生率。结果 研究组CD4+计数高于对照组， HIV病毒载量水平低于对照组，差异均有统计学意义（P<0.05），肾毒性、骨密度影响的发生率差异无统计学意义（P>0.05）。结论 拉米夫定+替诺福韦+克立芝三药联合可有效抑制HIV病毒在人体内的复制与扩散，延缓疾病进程，但对肾毒性、骨密度的影响较大。

Abstract

Objective: To explore and analyze the safety of different combinations of tenofovir tablets in the treatment of AIDS.
Methods: 98 patients with AIDS who received treatment in our hospital from February 2018 to February 2022 were selected as the research objects and randomly divided into the control group and the study group. The control group was treated with efaviren, tenofovir, and lamivudine, while the study group was treated with lamivudine, tenofovir, and clonidazole. After treatment, the incidence of lymphocyte counts, HIV viral load, clinical indicators, renal toxicity, and bone mineral density effects were compared between the two groups.
Results: The CD4+count in the study group was higher than that in the control group, and the HIV viral load level was lower than that in the control group, with significant differences (P<0.05). There was no significant difference in the incidence of nephrotoxicity and bone mineral density effects (P>0.05).
Conclusion  : The combination of lamivudine, tenofovir, and clonidazole can effectively inhibit the replication and diffusion of HIV virus in humans, delay the progression of the disease, but have a significant impact on renal toxicity and bone mineral density.